Literature DB >> 14573672

Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice.

Carole Dumas1, Anthony Muyombwe, Gaétan Roy, Claudine Matte, Marc Ouellette, Martin Olivier, Barbara Papadopoulou.   

Abstract

Leishmania is an intracellular pathogen that replicates inside macrophages. Activated macrophages produce a specific subset of cytokines that play an important role in the control of Leishmania infections. As part of our interest in developing suicide parasites that produce abortive infections for the purposes of vaccination, we engineered recombinant Leishmania major strains producing biologically active granulocyte-macrophage colony-stimulating factor (GM-CSF). We showed that GM-CSF is being produced in the phagosomes of infected macrophages and that it can be detected in the culture supernatants of both infected macrophages and extracellular parasites. Our data support the notion that GM-CSF secreted by both developmental forms of recombinant L. major can activate macrophages to produce high levels of proinflammatory cytokines such as interleukin-1beta (IL-1beta), IL-6, and IL-18 and various chemokines including RANTES/CCL5, MIP-1alpha/CCL3, MIP-1beta/CCL4, MIP-2/CXCL2, and MCP-1/CCL2, which enhance parasite killing. Indeed, GM-CSF-expressing parasites survive poorly in macrophages in vitro and produce delayed lesion development in susceptible BALB/c mice in vivo. Selective killing of intracellular Leishmania expressing cytokine genes capable of activating cellular responses may constitute a promising strategy to control and/or prevent parasitic infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14573672      PMCID: PMC219543          DOI: 10.1128/IAI.71.11.6499-6509.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  RNA polymerase I-mediated transcription of a reporter gene integrated into different loci of Leishmania.

Authors:  Nathalie Boucher; François McNicoll; Carole Dumas; Barbara Papadopoulou
Journal:  Mol Biochem Parasitol       Date:  2002-01       Impact factor: 1.759

2.  Monocyte chemotactic protein-1 stimulates the killing of leishmania major by human monocytes, acts synergistically with IFN-gamma and is antagonized by IL-4.

Authors:  U Ritter; H Moll
Journal:  Eur J Immunol       Date:  2000-11       Impact factor: 5.532

3.  Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor.

Authors:  Ivonise Follador; Cibele Araujo; Glória Orge; Lay Har Cheng; Lucas P de Carvalho; Olívia Bacellar; Roque P Almeida; Edgar M Carvalho
Journal:  Vaccine       Date:  2002-01-31       Impact factor: 3.641

4.  Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination.

Authors:  Barbara Papadopoulou; Gaétan Roy; Marie Breton; Christoph Kündig; Carole Dumas; Isabelle Fillion; Ajay K Singh; Martin Olivier; Marc Ouellette
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  Efficient immunity against Leishmania major in the absence of interleukin-6.

Authors:  N H Moskowitz; D R Brown; S L Reiner
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

6.  Leishmania-induced cellular recruitment during the early inflammatory response: modulation of proinflammatory mediators.

Authors:  Claudine Matte; Martin Olivier
Journal:  J Infect Dis       Date:  2002-02-06       Impact factor: 5.226

7.  Mice unresponsive to GM-CSF are unexpectedly resistant to cutaneous Leishmania major infection.

Authors:  C L Scott; L Roe; J Curtis; T Baldwin; L Robb; C G Begley; E Handman
Journal:  Microbes Infect       Date:  2000-08       Impact factor: 2.700

8.  Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models.

Authors:  G Roy; C Dumas; D Sereno; Y Wu; A K Singh; M J Tremblay; M Ouellette; M Olivier; B Papadopoulou
Journal:  Mol Biochem Parasitol       Date:  2000-10       Impact factor: 1.759

9.  Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection.

Authors:  K Ohkusu; T Yoshimoto; K Takeda; T Ogura; S Kashiwamura; Y Iwakura; S Akira; H Okamura; K Nakanishi
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

10.  Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease.

Authors:  R G Titus; G K DeKrey; R V Morris; M B Soares
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

View more
  18 in total

1.  Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis.

Authors:  Shraddha Kumari; Mukesh Samant; Prashant Khare; Pragya Misra; Sujoy Dutta; Bala Krishna Kolli; Sharad Sharma; Kwang Poo Chang; Anuradha Dube
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

2.  A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.

Authors:  Daniela P Lage; Patrícia A F Ribeiro; Daniel S Dias; Débora V C Mendonça; Fernanda F Ramos; Lívia M Carvalho; Daysiane de Oliveira; Bethina T Steiner; Vívian T Martins; Luísa Perin; Amanda S Machado; Thaís T O Santos; Grasiele S V Tavares; João A Oliveira-da-Silva; Jamil S Oliveira; Bruno M Roatt; Ricardo A Machado-de-Ávila; Antônio L Teixeira; Maria V Humbert; Eduardo A F Coelho; Myron Christodoulides
Journal:  NPJ Vaccines       Date:  2020-08-13       Impact factor: 7.344

3.  The transition of M-CSF-derived human macrophages to a growth-promoting phenotype.

Authors:  Kajal Hamidzadeh; Ashton T Belew; Najib M El-Sayed; David M Mosser
Journal:  Blood Adv       Date:  2020-11-10

4.  Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.

Authors:  Marie Breton; Michel J Tremblay; Marc Ouellette; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Reduced pathology following infection with transgenic Leishmania major expressing murine CD40 ligand.

Authors:  Ann E Field; Sagie Wagage; Sean M Conrad; David M Mosser
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

6.  CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice.

Authors:  Rene E Vasquez; Lynn Soong
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

7.  A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.

Authors:  Vivian T Martins; Mariana C Duarte; Miguel A Chávez-Fumagalli; Daniel Menezes-Souza; Cecília S P Coelho; Danielle F de Magalhães-Soares; Ana Paula Fernandes; Manuel Soto; Carlos A P Tavares; Eduardo A F Coelho
Journal:  Parasit Vectors       Date:  2015-07-11       Impact factor: 3.876

8.  An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis.

Authors:  Letícia Martins Dos Reis Lage; José Mário Barichello; Daniela Pagliara Lage; Débora Vasconcelos Costa Mendonça; Ana Maria Ravena Severino Carvalho; Marcella Rezende Rodrigues; Daniel Menezes-Souza; Bruno Mendes Roatt; Ricardo José Alves; Carlos Alberto Pereira Tavares; Eduardo Antonio Ferraz Coelho; Mariana Costa Duarte
Journal:  Parasitol Res       Date:  2016-07-01       Impact factor: 2.289

Review 9.  Transgenic Leishmania and the immune response to infection.

Authors:  L Beattie; K J Evans; P M Kaye; D F Smith
Journal:  Parasite Immunol       Date:  2008-02-04       Impact factor: 2.280

10.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.